China approves AstraZeneca-Daiichi Sankyo’s breast cancer therapy
13 Jul 2023
ADCDrug ApprovalClinical ResultPhase 3
Preview
Source: Pharmaceutical Technology
Enhertu is indicated for use in adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Credit: Nephron / commons.wikimedia.org.
The Chinese National Medical Products Administration has granted approval for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as a monotherapy to treat breast cancer.
An antibody-drug conjugate (ADC) targeting the HER2 protein, Enhertu is indicated for use in adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Paclitaxel Trevatide in Metastatic Breast Cancer GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Dovitinib Lactate in Breast Cancer GlobalData
View allCompanies IntelligenceAstraZeneca PlcDaiichi Sankyo Co LtdView all
These patients should have received a previous systemic treatment in the metastatic setting, or have experienced a recurrence of the condition during or within six months of receiving adjuvant chemotherapy.
The latest approval is based on data from Phase III DESTINY-Breast04 clinical trial.
Trial data showed that the therapy reduced disease progression or the risk of death by half, and boosted median overall survival by more than six months compared with physician’s choice of chemotherapy.
In February 2023, the ADC was approved for treating priorly treated unresectable or metastatic HER2-positive breast cancer.
AstraZeneca oncology business unit executive vice-president Dave Fredrickson stated: “The results from the DESTINY-Breast04 trial show Enhertu provides a significant improvement in outcomes compared to chemotherapy for patients whose tumours are determined to be HER2-low via routine testing.
“This approval is an important advance in the way breast cancer is classified and treated in China and supports our vision to bring Enhertu to more patients worldwide.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.